Siblings 圖書 [1/1] 會議論文/會議摘要 [115/179] Collection Statistics 近3年內發表的文件:58(17.58%) 含全文筆數:327(99.09%) 文件下載次數統計 下載大於0次:327(100.00%) 下載大於100次:313(95.72%) 檔案下載總次數:138681(77.76%) 最後更新時間: 2024-12-01 12:22 Top Upload Loading... Top Download Loading... Recent Submissions Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 51-60 of 330. (33 Page(s) Totally) << < 1 2 3 4 5 6 7 8 9 10 > >> View [10|25|50] records per page

Date	Title	Relation
2022-04	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials	Journal for Immunotherapy of Cancer. 2022 Apr;10(4):Article number e004273.
2022-02-24	Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway	International Journal of Molecular Sciences. 2022 Feb 24;23(5):Article number 2608.
2022-02-16	Current status of the spectrum and therapeutics of helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma	Cancers. 2022 Feb 16;14(4):Article number 1005.
2022-02-15	Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1	American Journal of Cancer Research. 2022 Feb 15;12(2):713-728.
2022-02	Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010)	International Journal of Urology. 2022 Feb;29(2):121-127.
2022-02	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr	Lancet Oncology. 2022 Feb;23(2):234-247.
2022-01	Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation	Journal of the Formosan Medical Association. 2022 Jan;121(1 Pt 1):170-180.
2022-01	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study	Gastric Cancer. 2022 Jan;25(1):207-217.
2021-11-30	Survival outcomes of management in metastatic gastric adenocarcinoma patients	Scientific Reports. 2021 Nov 30;11:Article number 23142.
2021-11-20	Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study	Therapeutic Advances in Medical Oncology. 2021 Nov 20;Article in Press.

Showing items 51-60 of 330. (33 Page(s) Totally) << < 1 2 3 4 5 6 7 8 9 10 > >> View [10|25|50] records per page